Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation in the airways, parenchyma and vessels, which can cause a structural remodeling with increased fibrosis that narrows and fixes the airway lumen. Transforming growth factor-b1 (TGF-b1), a multifunctional growth factor, was reported to be increased in the airways of COPD patients. In this study, we hypothesized that polymorphisms in the TGF-b1 gene would be associated with an accelerated rate of decline of forced expiratory volume in 1 s (FEV 1 ). Three polymorphisms, À509 (C-T), +869 (T-C) and +915 (G-C), located in TGFb1 gene were genotyped. We determined the prevalence of these polymorphisms in 590 continuing smokers who had the fastest (n ¼ 283) and slowest (n ¼ 307) rate of decline of lung function from the NHLBI Lung Health Study. There was no association between these TGF-b1 polymorphisms and the rate of decline of FEV 1 , but in a post-hoc analysis the genotype distribution at +869 was significantly different between high and low responders to methacholine (P ¼ 0:04). These data suggest that the T-C polymorphism at position +869 in the TGF-b1 gene contributes to airway hyperresponsiveness, but not to rapid decline of lung function.
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Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation in the airways, parenchyma and vessels where various inflammatory cells are increased and release a variety of mediators. 1 The injury and repair cycle caused by the chronic inflammation can result in structural airway remodeling with increased fibrosis 2, 3 that narrows and fixes the airway lumen. It is generally accepted that cigarette smoking is the most important risk factor for COPD. However, only 10-15% of smokers develop the severe impairment of pulmonary function associated with COPD. 4 The Global Initiative on Chronic Obstructive Lung Disease (GOLD) reported that the repeated exposure to pollutants, chronic or latent viral infection and genetic factors enhance the susceptibility to COPD in smokers. 5 The familial clustering of patients with early onset COPD 6 and the differences in the prevalence of COPD among different racial groups strongly suggest that genetic factors may contribute the susceptibility to COPD.
Transforming growth factor-b1 (TGF-b1) is multifunctional growth factor that has numerous biological effects such as induction of fibroblast proliferation and extracellular matrix production, decreased collagen degradation, 7 chemotaxis of macrophages and mast cells and inhibition of epithelial cell growth.
8 TGF-b1 is also a switching factor for IgA and induces production of IgA with or without LPS and IL4 stimulation. 9 Previous reports showed that TGF-b1 expression was increased in the airways of COPD patients. 1, 8, 10 On the other hand, lack of activation of latent TGF-b1-induced emphysema-like alveolar destruction in an animal model. 11 Wu et al. 12 reported an association between COPD and the Leu-Leu genotype at codon 10. The Leu allele is associated with lower production of TGF-b1 genotype and therefore the authors concluded that TGF-b1 could have a protective role in COPD. Importantly, this result was replicated in a larger COPD case-control study by Celedón et al. 13 The TGF-b1 gene contains several variants 14, 15 and we focused on three single nucleotide polymorphisms that had been associated with gene expression and/or susceptibility to disease in previous studies: a C-T transition at nucleotide À509 which is located in the 5 0 flanking region of the gene, a T-C transition at nucleotide +869 which leads to the Leu10Pro amino acid substitution and a G-C transversion at nucleotide +915 which leads to the Arg25Pro amino acid substitution.
We investigated whether these three polymorphisms of the TGF-b1 gene were associated with an accelerated rate of decline of forced expiratory volume in 1 s (FEV 1 ) in the Lung Health Study (LHS). We also investigated the association of these polymorphisms with airway hyperresponsiveness. The LHS, sponsored by the National Heart, Lung and Blood Institute, was a clinical trial of smoking intervention and bronchodilator usage on the progression of COPD. 16 This dataset provides an excellent opportunity to test the relationship between TGF-b1 gene polymorphisms and the rate of decline of FEV 1 .
Methods

Study participants
We performed a nested case control study of 283 Caucasian individuals who had the fastest decline of FEV 1 and 307
Caucasian individuals who had the slowest decline from 3216 study participants who continued to smoke during 5 years of follow-up in the LHS. Spirometry was performed annually over a period of 5 years as previously described. 16 Lung function was assessed as pre-bronchodilator FEV 1 % predicted, i.e. FEV 1 adjusted for age, height, and sex. 17 The rate of decline was expressed as the average decline in FEV 1 % predicted per year over the 5 years of follow-up. Arbitrary cut-off points of FEV 1 % predicted decrease X3.0%/ year and increase X0.4%/year were used for rapid decliners and non-decliners, respectively. Among 590 participants in this study methacholine responsiveness was measured in 568 ( Table 1 ). The experimental protocol for this study was approved by the Providence Health Care Research Ethics Board.
Since airway hyperresponsiveness is one of the risk factors of COPD 5 we used methacholine responsiveness as an additional outcome variable in this study. Measure ment of the responsiveness of the airways to methacholine was expressed as a dose-response slope, i.e. the difference between the lowest post-challenge in FEV 1 and baseline FEV 1 divided by the cumulative dose of metha choline administered (in units of % decline in FEV 1 /mmol of methacholine). 18 Due to the selection of the study participants the distribution of methacholine respon siveness was bimodal. Therefore, we used a dicho tomized variable for this analysis, i.e. low responsiveness (O'Connor slope X60) and high responsiveness (O'Connor slope p60).
Genotyping
As shown in Fig. 1 , detection of the polymorphisms of the TGF-b1 gene was performed using polymerase chain reaction (PCR)-restriction fragment length polymorphism methods. Briefly, to determine the genotype of the C-509T polymorphism, PCR was done using the forward primer (5 0 -GTC CCT CTG GGC CCA GTT TC-3 0 ) and the reverse primer (5 0 -GAG GGG GCA ACA GGA CAC CTT A-3 0 ) that has a mismatch (the underlined base) to introduce an Afl II restriction site into the PCR product when there is a C to T base exchange at À509. After amplification, the PCR products were digested overnight at 37 1C with five units of Afl II restriction enzyme. The C allele yielded a fragment of 178 bp, while the T allele yielded fragments of 159 and 19 bp. To determine the genotype of the T+869C and G+915C polymorphisms, PCR was done using the forward primer (5 0 -TTC CCT CGA GGC CCT CCT A-3 0 ) and the reverse primer (5 0 -GCC GCA GCT TGG ACA GGA TC-3 0 ), which were designed according to the published sequences. 19 After amplification, for T+869C genotyping the PCR products were digested overnight at 37 1C with five units of MspA1 I restriction enzyme. The T allele yielded fragments of 161, 67, 40 and 26 bp, while the C allele yielded fragments of 149, 67, 40, 26 and 12 bp. For G+915C genotyping, the PCR products were digested overnight at 37 1C with five units of Bgl I restriction enzyme. The G allele yielded fragments of 131, 103 and 60 bp, while the C allele yielded fragments of 131 and 163 bp. Genotypes were scored without knowledge of the phenotypes by two observers.
Data analysis
Demographic characteristics in the two study groups were compared by w 2 analysis for categorical variables and t-tests for continuous variables. The frequencies of the alleles and genotypes between rapid and non-decliner groups were compared by w 2 analyses for 3 Â 2 contingency tables, unless otherwise stated. Significant associations were also analyzed by logistic regression to adjust for potential confounding factors. P-values less than 0.05 were considered z Change in lung function over a 5-year period measured as pre-bronchodilator FEV 1 % predicted. Percent predicted values are adjusted for height, age and sex.
y Lung function at the start of the study measured as ml.
J Lung function at the start of the study measured as % predicted. z Percent change in FEV 1 from baseline in response to a bronchodilator. # Measurement of the responsiveness of the airways to methacholine expressed as percent decline in FEV 1 per final cumulative dose of methacholine administered (data only available for 568 participants).
ÃÃ O'Connor slope p60/O'Connor slope X60. significant. These analyses were performed with the JMP 5.1 program (SAS Institute Inc., Cary, NC, USA). Haplotype frequencies, linkage disequilibrium, and Hardy-Weinberg equilibrium were calculated using the Arlequin software package. 20 Linkage disequilibrium (the association between alleles of different polymorphisms in a population of unrelated individuals) was assessed by calculating the D 0 statistic. This is the coefficient of linkage disequilibrium D expressed as a proportion of its maximum value (D max ) given the observed allele frequencies.
Results
The characteristics of the 590 smokers are given in Table 1 . In the fast decline group, the range of values was from À3.0 to À8.8 in terms of change in % predicted FEV 1 per year. The corresponding range of absolute values was À78 to À366 ml per year. All individuals were Caucasian and there were significant differences in several potential confounding factors such as age, sex and cigarette-smoking history (pack-years) between fast/non-lung function decline groups. Therefore, the associations of alleles, genotypes and haplotypes with lung function were analyzed by logistic regression to adjust for these factors. Three polymorphisms in the TGF-b1 were determined in this association study. The distributions of C-509T, T+869C and G+915C genotypes in the rapid and non-decliner groups are detailed in Table 2 . The overall observed distribution of homozygotes and heterozygotes for each polymorphism conformed to expectations based on Hardy-Weinberg analysis. There was no association with rate of decline of lung function with any genotypes (Table 2 ) and the differences were not significant after adjustment for the significantly different baseline values (age, pack-years, gender and initial level of lung function). Furthermore, haplotype analysis of the three TGF-b1 polymorphisms did not reveal an association with rate of decline of lung function (Table 3 ). There was significant linkage disequilibrium between all three loci ( Table 4) .
In a post-hoc analysis, the distribution of +869 genotypes was significantly different in high responders to methacholine compared with the low responders ( Table 5) . Specifically, the frequency of the CC genotype was more than doubled in the high responders. This increased CC frequency remained significant after adjustment for age, gender, smoking history (pack-year), baseline lung function and rate of decline of lung function (odds ratio ¼ 3.0, 95% CI ¼ 1.2-7.0, P ¼ 0:01) when compared with the CT and TT individuals combined.
Discussion
In the present study, we investigated whether polymorphisms of the TGF-b1 gene were associated with the rate of decline of lung function in smokers. None of the genotypes or haplotypes had a statistically significant effect on the rate of decline of lung function. However, one of these polymorphisms, which is located at position +869 of the TGF- Genotyping assays were not successful for 21 samples for the À509 polymorphism and 27 samples for the T+869C polymorphism. Ã Fisher's exact test. Table 3 The haplotype frequencies estimated within the study patients. Loci are presented in the order À509, T+869C, G+915C. There was no significant difference in the haplotype distribution between the fast and non-decliner groups (P ¼ 0:76). The total number of haplotypes does not add up to 1180 because only individuals with complete genotypic data across the three polymorphisms were included in the analysis. b1 gene, was associated with airway hyperresponsiveness to methacholine.
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The T allele at À509 creates a putative YY1 transcription factor binding site 21 that has been associated with COPD, 13 asthma, 22 asthma severity, 23 higher serum TGF-b1, 24 higher total serum IgE 21 and increased YY1 binding and reporter gene activity. 22 Homozygosity (Pro/Pro) at codon 10 25,26 and homozygosity (Arg/Arg) at codon 25 27 are high producer genotypes of TGF-b1. The Leu10 isoform was associated with accelerated decline in lung function of patients with cystic fibrosis. 28 Wu et al. 12 reported that the Leu/Leu genotype at codon 10 was significantly increased in COPD patients compared with controls. These data are consistent with integrin a v b 6 knockout mice which developed emphysema that could be abrogated by transgenic expression of active TGF-b1 (11) . Celedón and colleagues 13 demonstrated linkage between the chromosomal region containing the TGF-b1 gene and lung function in a cohort of early onset COPD families. The same authors showed that the À509C and Leu10 alleles were significantly increased in COPD patients versus controls. 13 More recently, Su et al. 29 have shown that the À509C allele is increased in COPD patients from the Chinese population.
Therefore, the results of these genetic studies are consistent and suggest that decreased level of TGF-b1 is a risk factor for the development of COPD. However, TGF-b1 has a wide array of functions and it is not clear which are relevant if this observation is true. It is possible that TGF-b1 protects against decline in lung function or it may be involved in lung development or response to infection. In contrast, previous studies showed that TGF-b1 expression was increased in the airways of COPD patients. 1, 8, 10 There are several possible reasons that we did not replicate the previous associations of TGF-b1 polymorphisms and COPD. One reason is the difference in the phenotype of the study subjects. Wu et al., 12 Celedón et al. 13 and Su et al. 29 compared subjects who had already developed COPD with smokers who had normal lung function, whereas in this study we focused on the acceleration of decline in FEV 1 . The underlying pathology of COPD is mixture of airway and parenchyma lesions. TGF-b1 could have a protective role against the destruction of alveoli leading to emphysema but not against airway remodeling in COPD. It is even possible that TGF-b1 contributes to airway remodeling by producing extracellular matrix. Therefore, the impact on lung function may be less pronounced than for a molecule that protects against both pathological processes. The effect of the TGFb1 polymorphisms may only become evident after a long period of time and the individuals in this study were considerably younger than those in the previous studies. 12, 13, 29 Another reason for lack of replication is the number of the subjects in the study. Our study included more subjects than two of the previous studies, 12, 29 but fewer than the study of Celedón et al. 13 Therefore, we cannot rule out the possibility that the lack of association in this study was a false negative result.
The range of FEV 1 baseline levels in the fast decliners was 54.9-90.6% of predicted, and therefore a few of these individuals would not have been classified as COPD patients at the start of the study. However, the phenotype that we studied was rate of decline of lung function rather than COPD per se. The rationale for this was that rate of decline of lung function is a more precise phenotype than a single cross-sectional measurement of lung function. Lung function normally increases to a maximal value at adulthood and begins to decline 10-15 years later. COPD can develop because of a reduced maximal lung function, an earlier age of onset of decline and/or an accelerated rate of decline. Different genetic variants may influence these processes and therefore the study of rate of decline may allow a more genetically homogeneous phenotype to be studied.
Previous studies have shown that increased airway hyperresponsiveness to histamine was associated with accelerated decline in FEV 1 30 and airway hyperresponsiveness was identified as one of the risk factors that contribute to the development of COPD. 5 In this study, a post-hoc analysis found a significant association between +869 genotypes and airway hyperresponsiveness to methacholine. However, there was no significant correlation between TGFb1 polymorphisms and decline of FEV 1 and this may reflect the small numbers of participants in the high responder group.
In summary, there was no association between TGF-b1 polymorphisms and the rate of decline of FEV 1 , but the genotype distribution of the +869 amino acid substitution was significantly different between high and low responders to methacholine. These data suggest that the +869 polymorphism in the TGF-b1 gene contributes to airway hyperresponsiveness. 
